Pharma BD Deal Intelligence

Shire plc / ViroPharma Incorporated

2013 · Acquisition/Merger · $4.2B · Complete

Announcement Sentiment

Strongly positive

Shire to acquire ViroPharma at $50/share cash (~$4.2B); 27% premium to prior close. Strengthens rare disease franchise; expected to create $2B rare disease revenue base with $150M annual cost synergies by 2015.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Nov 11, 2013
Closed Jan 24, 2014
Deal value $4.2B
Deal type Acquisition/Merger
Therapeutic area Hereditary Angioedema (HAE)
Indications Hereditary Angioedema (HAE)
Key assets Cinryze (C1 esterase inhibitor)
Mechanism Plasma-derived C1 esterase inhibitor replacement

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals